Srinivas Nuggehally R
Drug Development, Discovery Research, Dr Reddy's Laboratories Limited, Bollaram Road, Miyapur, Hyderabad, India.
Biomed Chromatogr. 2006 May;20(5):383-414. doi: 10.1002/bmc.594.
The development of sound bioanalytical method(s) is of paramount importance during the process of drug discovery and development culminating in a marketing approval. Although the bioanalytical procedure(s) originally developed during the discovery stage may not necessarily be fit to support the drug development scenario, they may be suitably modified and validated, as deemed necessary. Several reviews have appeared over the years describing analytical approaches including various techniques, detection systems, automation tools that are available for an effective separation, enhanced selectivity and sensitivity for quantitation of many analytes. The intention of this review is to cover various key areas where analytical method development becomes necessary during different stages of drug discovery research and development process. The key areas covered in this article with relevant case studies include: (a) simultaneous assay for parent compound and metabolites that are purported to display pharmacological activity; (b) bioanalytical procedures for determination of multiple drugs in combating a disease; (c) analytical measurement of chirality aspects in the pharmacokinetics, metabolism and biotransformation investigations; (d) drug monitoring for therapeutic benefits and/or occupational hazard; (e) analysis of drugs from complex and/or less frequently used matrices; (f) analytical determination during in vitro experiments (metabolism and permeability related) and in situ intestinal perfusion experiments; (g) determination of a major metabolite as a surrogate for the parent molecule; (h) analytical approaches for universal determination of CYP450 probe substrates and metabolites; (i) analytical applicability to prodrug evaluations-simultaneous determination of prodrug, parent and metabolites; (j) quantitative determination of parent compound and/or phase II metabolite(s) via direct or indirect approaches; (k) applicability in analysis of multiple compounds in select disease areas and/or in clinically important drug-drug interaction studies. A tabular representation of select examples of analysis is provided covering areas of separation conditions, validation aspects and applicable conclusion. A limited discussion is provided on relevant aspects of the need for developing bioanalytical procedures for speedy drug discovery and development. Additionally, some key elements such as internal standard selection, likely issues of mass detection, matrix effect, chiral aspects etc. are provided for consideration during method development.
在药物发现与开发直至获得上市批准的过程中,开发完善的生物分析方法至关重要。尽管在发现阶段最初开发的生物分析程序不一定适合支持药物开发方案,但如有必要,可对其进行适当修改和验证。多年来已出现了几篇综述,描述了包括各种技术、检测系统、自动化工具在内的分析方法,这些方法可用于有效分离,提高许多分析物定量的选择性和灵敏度。本综述的目的是涵盖药物发现研究与开发过程不同阶段中需要进行分析方法开发的各个关键领域。本文涵盖的关键领域及相关案例研究包括:(a) 对据称具有药理活性的母体化合物和代谢物进行同步测定;(b) 用于确定治疗疾病的多种药物的生物分析程序;(c) 在药代动力学、代谢和生物转化研究中对手性方面的分析测量;(d) 为治疗益处和/或职业危害进行药物监测;(e) 分析来自复杂和/或较少使用基质的药物;(f) 在体外实验(代谢和通透性相关)和原位肠道灌注实验期间进行分析测定;(g) 确定主要代谢物作为母体分子的替代物;(h) 通用测定CYP450探针底物和代谢物的分析方法;(i) 前药评估的分析适用性——同时测定前药、母体和代谢物;(j) 通过直接或间接方法对母体化合物和/或II相代谢物进行定量测定;(k) 在特定疾病领域分析多种化合物和/或在具有临床重要性的药物相互作用研究中的适用性。提供了一个表格,列出了选定的分析示例,涵盖分离条件、验证方面和适用结论等领域。还就快速药物发现与开发所需生物分析程序的相关方面进行了有限的讨论。此外,还提供了一些关键要素,如内标选择、质量检测可能出现的问题、基质效应、手性方面等,以供方法开发时考虑。